secwatch / observer
8-K filed May 7, 2026, 7:59 PM ET ticker ARWR CIK 0000879407
earnings confidence high sentiment negative materiality 0.80

Arrowhead Q2 revenue $73.7M, net loss $0.93; REDEMPLO strong; $930M capital raise; Madrigal license

ARROWHEAD PHARMACEUTICALS, INC.

2026-Q2 EPS reported -$0.73 revenue$337,770,000
item 2.02item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0000879407-26-000045
form_type
8-K
ticker
ARWR
cik
0000879407
company_name
ARROWHEAD PHARMACEUTICALS, INC.
filed_at
2026-05-07T23:59:59+00:00
discovered_at
2026-05-14T18:02:33.852772+00:00
generated_at
2026-05-14T22:22:39.545000+00:00
sec_items
["2.02", "9.01"]
event_type
earnings
sentiment
negative
materiality_score
0.8
calibrated_materiality_score
0.8
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0000879407-26-000045
json_url
https://secwatch.observer/filing/0000879407-26-000045.json
markdown_url
https://secwatch.observer/filing/0000879407-26-000045.md
text_url
https://secwatch.observer/filing/0000879407-26-000045.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/879407/000087940726000045/0000879407-26-000045-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/879407/000087940726000045/arwr-20260507.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

b4cd0f6b0ab82622c1db7c6dbdd95dd0f81240e0

ARROWHEAD PHARMACEUTICALS, INC. reported financial results for fiscal 2026 second quarter ended March 31, 2026.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026.

SEC 8-K Item 2.02 confidence 0.9 SEC evidence

Comparable filings

VSCO

Victoria's Secret Q1 sales up 15% to $1.56B, beats guidance; raises FY2026 outlook

Victoria's Secret & Co. June 2, 2026, 7:01 AM ET earnings Items 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026.

Comparable filing

The Company reported net sales of $1.560 billion for the first quarter of 2026, an increase of 15% compared to net sales of $1.353 billion for the first quarter of 2025 and above the previously communicated guidance range of $1.490 billion to $1.525 billion. Total comparable sales for the first quarter of 2026 increased 13%. The Company reported operating income for the first quarter of 2026 of $76 million compared to operating income of $20 million in the first quarter of 2025. Net income was $48 million, or $0.56 per diluted share, for the first quarter of 2026 compared to net loss of $2 million, or $0.02 per diluted share, for the first quarter of 2025.

Filing page SEC filing

SIG

Signet Q1 sales $1.6B, SSS +1.8%; raises FY27 adjusted EPS guidance

SIGNET JEWELERS LTD June 2, 2026, 6:54 AM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026.

Comparable filing

On June 2, 2026, Signet Jewelers Limited (the "Company") issued a press release announcing results for the first quarter ended May 2, 2026.

Filing page SEC filing

DG

Dollar General Q1 EPS $2.00 beats expectations; raises FY2026 EPS guidance

DOLLAR GENERAL CORP June 2, 2026, 6:54 AM ET earnings Items 2.02, 5.07, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026.

Comparable filing

(NYSE: DG) today reported financial results for its first quarter (13 weeks) ended May 1, 2026. First Quarter Fiscal Year 2026 Highlights · Net Sales Increased 3.4% to $10.8 Billion · Same-Store Sales Increased 2.0% · Operating Profit Increased 10.8% to $638.5 Million · Diluted Earnings Per Share (“EPS”) Increased 12.4% to $2.00 · Cash Flow From

Filing page SEC filing

HIVE

HIVE FY2026 revenue $297.8M (+158% YoY); GAAP net loss $148.4M

HIVE Digital Technologies Ltd. June 2, 2026, 6:23 AM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026.

Comparable filing

EXHIBIT 99.1 HIVE Digital Technologies Ltd.: Exhibit 99.1 - Filed by newsfilecorp.com Exhibit 99.1 HIVE DIGITAL TECHNOLOGIES LTD. HIVE Achieves FY2026 Total Revenue of $297.8 Million (+158% YoY), HIVE's BUZZ HPC Positioned for Growth This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated

Filing page SEC filing

DCI

Donaldson Q3 FY2026 sales $995.1M (+5.8%), adj. EPS $1.06 (+7.1%)

DONALDSON Co INC June 1, 2026, 5:41 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026.

Comparable filing

press release is furnished herewith as Exhibit 99.1. --- EX-99.1 (EX-99.1) --- Donaldson Reports Record Third Quarter Fiscal 2026 Sales and Earnings Third quarter sales of $995.1 million, up 5.8% Operating margin of 15.6%; All-time high adjusted operating margin of 16.6% GAAP EPS of $1.00; Adjusted EPS of $1.06, up 7.1% Closed margin-accretive Facet acquisition,

Filing page SEC filing

GMRS

GMR Solutions Q1 revenue $1.46B (+6.6% YoY), net income $106M (+180% YoY), guides FY26 rev $5.9-6.2B

GMR Solutions Inc. June 1, 2026, 4:45 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026.

Comparable filing

today announced financial results for the first quarter ended March 31, 2026, and full year 2026 financial guidance. First Quarter 2026 Financial Highlights ● Net revenue of $1,457.6 million, up 6.6% compared to $1,367.4 million in the first quarter of 2025 ● Net income of $106.3 million, up 179.7% compared to $38.0 million in the first quarter of 2025 ● Adjusted

Filing page SEC filing

HPE

HPE Q2 FY26: record revenue $10.7B (+40%), raises FY26 guidance, introduces FY27 framework

Hewlett Packard Enterprise Co June 1, 2026, 4:09 PM ET earnings Items 1.01, 2.02, 5.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026.

Comparable filing

gross margin, and non-GAAP diluted net EPS, as well as its highest-ever free cash flow generation for a second quarter. Second Quarter Fiscal 2026 Financial Results • Revenue : $10.7 billion, up 40% from the prior-year period • Gross margins : ◦ GAAP of 36.5%, up 810 basis points from the prior-year period and up 60 basis points sequentially ◦ Non-GAAP (1) of 36.9%,

Filing page SEC filing

CRDO

Credo Q4 revenue $437M (+157% YoY); guides Q1 $465-475M; CEO awarded 1.44M performance-based RSUs

Credo Technology Group Holding Ltd June 1, 2026, 4:08 PM ET earnings Items 2.02, 5.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026.

Comparable filing

On June 1, 2026, Credo Technology Group Holding Ltd (the "Company") issued a press release announcing its financial results for the fiscal year ended May 2, 2026.

Filing page SEC filing

Source: SEC EDGAR
accession 0000879407-26-000045
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.